1. Home
  2. INLF vs MBIO Comparison

INLF vs MBIO Comparison

Compare INLF & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

INLF

INLIF LIMITED

HOLD

Current Price

$2.78

Market Cap

3.5M

Sector

Industrials

ML Signal

HOLD

MBIO

Mustang Bio Inc.

HOLD

Current Price

$0.41

Market Cap

4.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INLF
MBIO
Founded
2016
2015
Country
China
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5M
4.1M
IPO Year
2023
2023

Fundamental Metrics

Financial Performance
Metric
INLF
MBIO
Price
$2.78
$0.41
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 1.0M
33.0K
Earning Date
09-24-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 98.99
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$405.45
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.02
$0.38
52 Week High
$9.91
$1.69

Technical Indicators

Market Signals
Indicator
INLF
MBIO
Relative Strength Index (RSI) 40.11 23.47
Support Level $2.38 N/A
Resistance Level $4.92 $0.56
Average True Range (ATR) 0.54 0.03
MACD -0.08 -0.01
Stochastic Oscillator 0.65 11.48

Price Performance

Historical Comparison
INLF
MBIO

About INLF INLIF LIMITED

INLIF Ltd, through its subsidiary, is engaged in the research, development, manufacturing, and sales of injection molding machine-dedicated manipulator arms. In addition, it offers installation and warranty services for manipulator arms, and accessories and raw materials for manipulator arms. Its portfolio includes injection molding machine-dedicated manipulator arms, including transverse single and double-axis manipulator arms, transverse and longitudinal multi-axis manipulator arms, and large bullhead multi-axis manipulator arms.

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: